Drug discovery companies identify, validate and develop new therapeutic candidates for the prevention and treatment of disease. The sector combines biology, chemistry, data science and clinical expertise to bring new medicines from concept to clinic.
This category includes companies working on:
Browse 422 UK drug discovery companies below.
Novel peptide therapeutics targeting obesity and type 2 diabetes
Dia Beta Labs is a preclinical-stage biotechnology company developing first-in-class therapeutic peptides for metabolic disease. Spun out of the Diabetes Research Group at Ulster…
Clinical-stage precision oncology developing first-in-class TACC3 inhibitor therapeutics
Coiled Therapeutics is a UK-listed, clinical-stage oncology company developing precision cancer therapeutics against structurally complex, previously undruggable targets. Its lead…
Antigenic immunomodulation therapies targeting autoimmune disease
Phaim Pharma is a biotech company developing disease-modifying therapeutics for autoimmune conditions using its proprietary platform. The platform is designed to reset the immune…
Integrated contract drug discovery from Cambridge and India
o2h is a contract research organisation operating an integrated drug discovery platform from Cambridge, UK, and Ahmedabad, India. Core services span medicinal chemistry, biology,…
Antibody discovery biotech targeting GPCRs in inflammatory disease
DJS Antibodies is a biotechnology company developing monoclonal antibody therapeutics against G protein-coupled receptors and other previously intractable disease targets. Its…
Phenotypic screening platform for targeted protein degradation drug discovery
PhoreMost is a drug discovery company developing a phenotypic screening platform to identify and prosecute previously undruggable disease targets. The platform systematically…
Clinical-stage bispecific antibody therapies for cancer and blood disease
NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, haematological malignancies, and autoimmune diseases. Its proprietary platform…
Targeting mitochondrial dysfunction in neurodegeneration
NRG Therapeutics is a clinical-stage neuroscience company developing small molecule inhibitors of the mitochondrial permeability transition pore as disease-modifying treatments…
Multiplexed imaging platform for therapeutic mechanism of action discovery
Micrographia Bio is a biotechnology company developing a spatial proteomics platform for drug discovery. Its technology combines highly multiplexed microscopy with…
Preclinical neuroscience CRO for translational drug development research
Transpharmation is a preclinical neuroscience contract research organisation providing translational pharmacology services to pharmaceutical and biotechnology companies. The…
AI-ready cellular perturbation datasets for drug discovery
CellCodex is a Cambridge-based company generating large-scale cellular perturbation datasets for the training of foundation AI models in biology. The company combines CRISPR…
Personalised cancer treatment selection using in vivo drug screening
Vivan Therapeutics is a London-based biotech developing a personalised cancer therapeutics platform. The company's Personal Discovery Process sequences a patient's tumour genome,…